Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
December 07, 2020 08:00 ET
|
BioSight Ltd.
Expanded data set supports efficacy across key measures including complete remission and MRD(-) rates, duration of response and overall survival Durable responses achieved as monotherapy with...
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
December 02, 2020 08:00 ET
|
BioSight Ltd.
AIRPORT CITY, Israel, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
November 05, 2020 10:15 ET
|
BioSight Ltd.
AIRPORT CITY, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
August 04, 2020 08:00 ET
|
BioSight Ltd.
AIRPORT CITY, Israel, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies
July 21, 2020 08:30 ET
|
BioSight Ltd.
AIRPORT CITY, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
Biosight to Present at the Jefferies 2020 Virtual Healthcare Conference
May 26, 2020 08:30 ET
|
BioSight Ltd.
AIRPORT CITY, Israel, May 26, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.
May 18, 2020 09:00 ET
|
BioSight Ltd.
AIRPORT CITY, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs
March 11, 2020 09:44 ET
|
BioSight Ltd.
AIRPORT CITY, Israel, March 11, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...